Hikal Limited
All news and filings related to Hikal Limited.
View all news & filings- Medium impact
Hikal Ltd. receives 'Crisil ESG 65' rating for FY 2025-26
Hikal Limited received a 'Crisil ESG 65' rating for FY 2025-26 from Crisil ESG Ratings & Analytics Limited. The rating highlights strong performance in renewable energy usage, waste recycling, and water management. The company also showed good practices in employee safety, stakeholder relations, and corporate governance.
Read the summary - Low impact
Hikal Ltd. Closes Trading Window from Oct 1 for Q2 FY27 Results
Hikal Limited will close its trading window from October 1, 2026. The closure is to prevent insider trading until 48 hours after the declaration of financial results for the quarter and half-year ending September 30, 2026. This is a routine compliance measure.
Read the summary - Medium impact
Hikal Shareholders Approve Sameer Hiremath's Appointment as Chairman & MD at 38th AGM
Hikal shareholders approved Sameer Hiremath's appointment as Chairman & MD for a five-year term from Oct 1, 2026, to Sep 30, 2031, at the 38th AGM. Audited financials for FY2025-26 and a ₹0.40 dividend were also approved. The company commenced Personal Care product manufacturing in Gujarat.
Read the summary - Medium impact
Hikal Limited holds 38th AGM, approves financial statements and declares dividend
Hikal Limited's 38th AGM on September 23, 2026, approved FY26 financial statements and a total dividend of ₹0.60 per share for FY26. Mr. Sameer Hiremath was appointed Chairman & MD, and Mr. Sarangan Suresh was re-appointed as Director. Remuneration for directors and cost auditors was also approved.
Read the summary - Medium impact
Hikal Ventures into Personal Care with New cGMP Panoli Facility Starting Commercial Production
Hikal Limited has commenced commercial production at its new cGMP facility in Panoli, Gujarat, marking its entry into the personal care market. The facility will focus on second-generation UV filters for the skin care category. This expansion is part of Hikal's broader strategy to diversify its business platforms.
Read the summary - Low impact
Hikal Limited Announces Analyst/Institutional Investor Meet on Sep 4, 2026
Hikal Limited will host an in-person group meeting with analysts and institutional investors on September 4, 2026, at its Pune R&D center. The discussions will be based on publicly available information.
Read the summary - Low impact
Hikal Ltd. announces 38th AGM on Sept 23, dividend record date Sept 4
Hikal Limited will hold its 38th AGM on September 23, 2026, via VC/OAVM. The record date for the final dividend for FY26 is September 4, 2026. Remote e-voting is open from September 19 to September 22, 2026. The cut-off date for voting eligibility is September 16, 2026.
Read the summary - Low impact
Hikal Limited Announces 38th AGM on Sep 23, 2026, to discuss FY26 Annual Report
Hikal Limited will hold its 38th AGM on September 23, 2026, via video conference. The company is sharing its FY26 Annual Report online. Shareholders with physical shares are urged to update KYC details by April 1, 2024, to continue receiving payments like dividends electronically.
Read the summary - Low impact
Hikal Limited Announces 38th Annual General Meeting and Releases FY26 Annual Report
Hikal Limited released its Annual Report for FY26 and announced its 38th AGM. The report details INR 17,126 Million revenue and 13.6% EBITDA margin. Key developments include HPAPI lab operationalization and cGMP Pilot Plant commissioning. The company achieved an EcoVadis Gold Medal and aims for INR 500+ crore revenue from Personal Care by 2029-30.
Read the summary - Medium impact
Hikal Limited Announces 38th AGM on Sep 23, 2026, to discuss FY26 results and dividends.
Hikal Limited will hold its 38th AGM on September 23, 2026, via VC/OAVM. Key agenda items include adopting FY26 financial statements and approving a total dividend of ₹0.60 per share. The appointment of Sameer Hiremath as CMD and revised remuneration for Sarangan Suresh will also be discussed.
Read the summary - Low impact
Hikal Limited Announces Final Dividend of ₹0.40/Share, Sets Record Date for Sep 4
Hikal Limited recommended a final dividend of ₹0.40 per equity share for FY 2025-26. The dividend requires shareholder approval at the AGM on September 23, 2026. The record date for dividend eligibility is September 4, 2026. Shareholders must submit tax-related documents by September 10, 2026, to ensure correct TDS deduction.
Read the summary - Medium impact
Hikal Ltd. Announces 38th AGM on Sept 23, 2026; Recommends Dividend
Hikal Limited's 38th AGM is scheduled for September 23, 2026. The board recommended a final dividend of ₹0.40 and an interim dividend of ₹0.20 per share for FY 2025-26. The record date for dividend payment is September 04, 2026.
Read the summary - Medium impact
Hikal Ltd. Announces 38th AGM on Sep 23, 2026, Sets Sep 4 Record Date for Final Dividend
Hikal Limited will hold its 38th AGM on September 23, 2026, via video conference. The Record Date for determining eligibility for the final dividend for FY25-26 is set as September 4, 2026. The dividend, if declared at the AGM, will be paid by October 23, 2026.
Read the summary - Low impact
Hikal Ltd. Fixes Sep 4, 2026 as Record Date for Final Dividend & Sep 23, 2026 for 38th AGM
Hikal Limited's 38th AGM is on Sep 23, 2026. Sep 4, 2026 is the record date for the FY25-26 final dividend. The dividend, if declared at the AGM, will be paid by Oct 23, 2026.
Read the summary - Medium impact
Hikal Appoints Sameer Hiremath as Chairman & MD for 5 Years
Hikal Limited's Board approved the appointment of Mr. Sameer Hiremath as Chairman and Managing Director. The appointment is for five years, from October 1, 2026, to September 30, 2031, pending shareholder approval. Mr. Hiremath has nearly three decades of experience with the company.
Read the summary - Low impact
Hikal Ltd. Informs Shareholders About Special Window for Physical Securities Transfer
Hikal Limited has opened a special window from February 5, 2026, to February 4, 2027, for transferring and dematerialising physical securities. This applies to transfer deeds executed before April 1, 2019. Shares will be issued in demat mode and subject to a one-year lock-in.
Read the summary - High impact
Hikal Ltd. Q1 FY27 Earnings Call Transcript Released; FY27 Revenue Growth Expected at 14-16%
Hikal Limited reported Q1 FY27 revenue of ₹403 crore and EBITDA margin of 9.2%. The company expects FY27 revenue growth of 14-16% and EBITDA growth of 25-30%. The Pharmaceutical business is recovering, while the Animal Health business targets ₹400 crore by FY30 with 20%+ EBITDA margins. The Personal Care segment is projected to reach ₹200 crore in three years with 20%+ EBITDA margins. US FDA re-inspection is anticipated by year-end, with improved revenue and margins expected in FY28.
Read the summary - Low impact
Hikal Limited Publishes Q1 FY27 Financial Results
Hikal Limited announced its Q1 FY27 financial results on August 07, 2026. The results were published in Business Standard and Mumbai Lakshadeep newspapers. This is a regulatory filing made available on the company's website.
Read the summary - Low impact
Hikal Ltd. releases audio recording of Q1 FY27 earnings conference call
Hikal Limited has released the audio recording of its earnings conference call for the quarter ended June 30, 2026. The call was held on August 6, 2026. The recording is available on the company's website.
Read the summary - Medium impact
Hikal Q1 FY27 Revenue at ₹403 Cr, EBITDA Margins Expand 260 bps YoY
Hikal Limited reported Q1 FY27 revenue of ₹403 crore, up 6.2% YoY. EBITDA grew 47.4% to ₹37 crore with margins expanding 260 bps to 9.2%. Pharmaceuticals revenue rose 15.2% to ₹233 crore. The company expects stepwise recovery in revenues and profitability in FY27.
Read the summary - Medium impact
Hikal Limited Q1 FY27 Results: Revenue ₹403 Cr, EBITDA ₹37 Cr, Pharma Growth 15.2%
Hikal Limited reported Q1 FY27 revenue of ₹403 Cr, up 6.2% YoY, with EBITDA at ₹37 Cr, up 47.4% YoY. The Pharmaceutical business grew 15.2% YoY to ₹233 Cr. The company is nearing completion of its US FDA remediation plan and received an EcoVadis Gold rating.
Read the summary - Medium impact
Hikal Ltd. Q1 FY27 Results: Net Loss of ₹7.5 Crore, Revenue at ₹402.8 Crore
Hikal Limited reported a consolidated net loss of ₹7.4 crore for Q1 FY27, with revenue at ₹402.8 crore. Standalone net loss was ₹7.5 crore. The trading window reopens on August 09, 2026. An ongoing environmental law matter and a USFDA warning letter continue to be noted.
Read the summary - Low impact
Hikal Announces Q1 FY27 Earnings Conference Call for August 6, 2026
Hikal Limited has scheduled its Q1 FY27 earnings conference call for August 6, 2026, at 5:00 PM IST. The call will discuss financial and operational performance for the quarter ended June 30, 2026. Key management, including the MD and CFO, will participate.
Read the summary - Medium impact
Hikal Awarded EcoVadis Gold Medal for Sustainability Excellence
Hikal Limited received the EcoVadis Gold Medal, ranking in the top 5% globally. The company scored 84/100, placing it in the 97th percentile. This award recognizes Hikal's commitment to sustainability across environmental, labor, ethics, and procurement practices. The rating is valid until July 2027.
Read the summary - Low impact
Hikal Ltd. Submits Certificate Under SEBI (Depositories and Participants) Regulations, 2018
Hikal Limited submitted a confirmation certificate for Q1 FY27 from its RTA, MUFG Intime India Private Limited, as per SEBI regulations. The certificate confirms processing of dematerialized securities for the quarter ended June 30, 2026.
Read the summary - Medium impact
Hikal Ltd. Shareholders Approve Appointment of Sandip Parikh as Independent Director
Hikal Limited shareholders approved the appointment of Mr. Sandip Parikh as an Independent Director. The special resolution passed with 99.9865% of votes in favor. Mr. Parikh's appointment is for a five-year term starting May 27, 2026. The e-voting concluded on July 4, 2026.
Read the summary - Low impact
Hikal Ltd. Notifies Shareholders About Special Window for Physical Securities
Hikal Limited has opened a special window for shareholders to transfer and dematerialise physical securities. This window is open from February 05, 2026, to February 04, 2027, for shares with transfer deeds executed before April 01, 2019. Eligible shareholders must submit requests with requisite documents to Hikal or its RTA.
Read the summary - Low impact
Hikal Limited Seeks Shareholder Approval for Sandip Parikh's Independent Director Appointment
Hikal Limited is conducting a postal ballot for shareholders to approve the appointment of Mr. Sandip Parikh as an Independent Director. The remote e-voting period is from June 05, 2026, to July 04, 2026. Mr. Parikh, a Chartered Accountant and Law Graduate, has 38 years of experience.
Read the summary - Medium impact
Hikal Limited Releases Q4 FY26 Earnings Transcript; Discusses Financial Performance and Growth Strategies
Hikal Limited's Q4 FY26 revenue was ₹519 crore with EBITDA margins at 20.3%. FY26 revenue reached ₹1,713 crore, with EBITDA margins of 12.9%. The company is recovering from past compliance issues and expects growth to return. Investments in new facilities and capabilities are strengthening its pharma and animal health businesses.
Read the summary - Low impact
Hikal Limited: Promoter Group Shares Unencumbered as of FY26
Hikal Limited confirms that shares held by Kalyani Investment Company Limited (31.36%) and BFIL Investment Limited (2.65%) were unencumbered as of March 31, 2026. This declaration is in line with SEBI Takeover Regulations for FY2025-26.
Read the summary - Low impact
Hikal Ltd. Sends Reminder Letters for Unclaimed Dividend 2018-19, Publishes in Newspapers
Hikal Limited is sending reminder letters to shareholders for unclaimed final dividends from FY 2018-19. Shares of those who haven't claimed for seven years will be transferred to IEPF by September 5, 2026. Newspaper publications and website updates are being provided for affected shareholders.
Read the summary - Low impact
Hikal Ltd. Publishes Q4 FY26 Financial Results Newspaper Advertisement
Hikal Limited published its Q4 FY26 financial results in newspapers on May 28, 2026. The announcement was made in accordance with SEBI regulations and is also available on the company's website. This is a routine regulatory filing.
Read the summary - Low impact
Hikal Limited: Audio Recording of Q4FY26 Earnings Conference Call Available
Hikal Limited has released the audio recording of its earnings conference call for the quarter and financial year ended March 31, 2026. The call took place on May 27, 2026, and the recording is available on the company's website.
Read the summary - Medium impact
Hikal Limited Q4 FY26 Results: Revenue ₹519 Cr, EBITDA Margin 20.3%
Hikal Limited reported Q4 FY26 revenue of ₹519 crore and EBITDA margin of 20.3%. Full-year FY26 revenue was ₹1,713 crore with a 12.9% EBITDA margin. The company sees improvement in Pharma and Crop Protection segments and expects new contributions from Specialty Chemicals and Personal Care from FY27. A total dividend of 30% was declared.
Read the summary - Medium impact
Hikal Appoints Ravi Khadabadi as President; Confirms No Financial Impact from Employee Irregularities
Hikal Limited appointed Ravi Khadabadi as President-Crop Protection & Specialty Chemicals. The company also confirmed no financial impact from past employee irregularities involving preponement of sales, with corrective actions and employee dismissals implemented.
Read the summary - Medium impact
Hikal Appoints Ravi Khadabadi as President; Clarifies Past Irregularities
Hikal Limited appointed Ravi Khadabadi as President-Crop Protection & Specialty Chemicals on May 27, 2026. The company also clarified past revenue recognition irregularities, stating they were limited to premature recognition of genuine sales with no impact on current/previous periods. Involved employees have been terminated.
Read the summary - Medium impact
Hikal Ltd. Board Approves Audited FY26 Results; Recommends 20% Final Dividend
Hikal Limited's Board approved audited FY26 results and recommended a 20% final dividend (₹0.40/share), totaling 30% for the year. Mr. Sandip Parikh was appointed as an Additional Independent Director. The company reported an impairment charge of ₹471 million and a tax provision reversal of ₹107 million.
Read the summary - Medium impact
Hikal Recommends 20% Final Dividend; Appoints Sandip Parikh as Independent Director
Hikal Limited's Board approved audited FY26 results and recommended a 20% final dividend. Mr. Sandip Parikh was appointed as an Independent Director for five years. The trading window reopens May 30, 2026. Q4 FY26 profit was ₹146 million; FY26 net loss was ₹487 million due to a ₹471 million impairment charge.
Read the summary - Medium impact
Hikal Ltd. Approves FY26 Audited Results, Recommends 20% Final Dividend, Appoints Sandip Parikh as Independent Director
Hikal Limited's Board approved FY26 audited results, recommending a 20% final dividend. Mr. Sandip Parikh was appointed as an Independent Director for five years. The company reported a profit of ₹85 million for Q4 FY26, impacted by a ₹471 million impairment charge. A USFDA warning letter affected Pharma Segment sales.
Read the summary - Low impact
Hikal Reschedules Q4 & FY26 Earnings Conference Call to May 27, 5:30 PM IST
Hikal Limited has rescheduled its Q4 & FY26 earnings conference call to May 27, 2026, at 5:30 PM IST. The call will discuss the company's financial and operational performance for the period ending March 31, 2026. Key management will participate.
Read the summary - Low impact
Hikal Limited Schedules Q4 & FY26 Earnings Conference Call for May 27, 2026
Hikal Limited will host an earnings conference call on May 27, 2026, at 4:30 PM IST to discuss financial and operational performance for Q4 and FY26 ended March 31, 2026. Key management personnel will participate.
Read the summary - Low impact
Hikal Ltd.: Vimaldeep Kulshrestha, President- Crop Protection, Retires on April 14, 2026
Hikal Limited announces the retirement of Mr. Vimaldeep Kulshrestha, President- Crop Protection. He will cease his employment with the company on April 14, 2026, upon superannuation. This change is in accordance with SEBI regulations.
Read the summary - Low impact
Hikal Ltd. Clarifies EPS Discrepancy in XBRL Filing
Hikal Limited corrected an inadvertent error in its XBRL filing for financial results submitted on November 13, 2025. The EPS for the quarter ended September 30, 2025, was incorrectly stated but has now been clarified as ₹(2.81). The year-to-date EPS is ₹(4.65).
Read the summary - Low impact
Hikal Limited Announces Newspaper Publication on Shareholder Information
Hikal Limited announced a Special Window for physical securities transfer and dematerialisation from Feb 5, 2026, to Feb 4, 2027. A second 100-Day Campaign, Saksham Niveshak, runs from April 1 to July 9, 2026, for KYC and unclaimed dividend updates. Shareholders should contact MUFG Intime India Pvt. Ltd.
Read the summary - Low impact
Hikal Limited: Promoter Confirms No Share Encumbrances for FY26
Hikal Limited's promoters and PAC have confirmed no encumbrances were made on their shares during FY26. This disclosure under SEBI Takeover Regulations was made on April 1, 2026, covering the period up to March 31, 2026.
Read the summary - Low impact
Hikal Ltd. Submits SEBI Compliance Certificate for Q4FY26
Hikal Limited submitted a SEBI compliance certificate for the quarter ended March 31, 2026. The certificate confirms the processing of dematerialised securities by the RTA, MUFG Intime India Private Limited, adhering to regulatory timelines.
Read the summary - Low impact
Hikal Limited: Trading Window Closure for Q4 FY26 Financial Results
Hikal Limited is closing its trading window from April 1, 2026. This closure is in effect until 48 hours after the declaration of financial results for the quarter and year ending March 31, 2026. The company is adhering to SEBI regulations.
Read the summary - Medium impact
Hikal Limited: Promoter Group Entity Castilia Life Sciences LLP Acquires 3,02,31,914 Shares
Hikal Limited's promoter group entity, Castilia Life Sciences LLP, has acquired 3,02,31,914 equity shares (24.52%) via conversion of Castilia Life Sciences Private Limited. The conversion was approved on February 17, 2026. This update pertains to substantial acquisition and promoter group changes.
Read the summary - Low impact
Hikal Ltd.: Promoter Group Entity Castilia Life Sciences Converts to LLP
Castilia Life Sciences Private Limited, a promoter group entity of Hikal Limited, has been converted into a Limited Liability Partnership (LLP) and is now known as Castilia Life Sciences LLP. The conversion, approved by the Ministry of Corporate Affairs, was effective from February 17, 2026.
Read the summary - Medium impact
Hikal Limited Q3 FY26 Earnings Call Transcript Released
Hikal Limited reported Q3 FY26 consolidated revenue of ₹494 crore and EBITDA of ₹83 crore, marking a return to operational profitability. An interim dividend of ₹0.2 per share was approved. The Pharmaceutical segment revenue was ₹337 crore with a 12.3% EBIT margin. The Crop Protection segment revenue was ₹157 crore with a 3% EBIT margin. The company expects meaningful revenue from the Personal Care segment starting FY27.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio